PROCEPT BioRobotics (PRCT) EBITDA (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of EBITDA data on file, last reported at -$31.7 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$31.7 million, down 28.69% year-over-year; the trailing twelve-month figure through Mar 2026 was -$102.7 million (down 14.02% YoY), and the FY2025 annual result was -$95.6 million, down 4.67% from the prior year.
• EBITDA fell to -$31.7 million in Q1 2026 per PRCT's latest filing, from -$29.8 million in the prior quarter.
• Over five years, EBITDA peaked at -$17.2 million in Q1 2022 and troughed at -$31.7 million in Q1 2026.
• A 5-year average of -$24.2 million and a median of -$24.6 million in 2025 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2024: EBITDA tumbled 65.64% in 2023, then jumped 31.7% in 2024.
• A 5-year view of EBITDA shows it stood at -$28.4 million in 2022, then climbed by 3.45% to -$27.4 million in 2023, then surged by 31.7% to -$18.7 million in 2024, then sank by 59.42% to -$29.8 million in 2025, then decreased by 6.18% to -$31.7 million in 2026.
• Business Quant data shows PRCT's EBITDA at -$31.7 million in Q1 2026, -$29.8 million in Q4 2025, and -$21.2 million in Q3 2025.